![](https://clsbluesky.law.columbia.edu/wp-content/uploads/sites/2/2022/11/horwich-e1667749338522.jpeg?w=150)
![](https://clsbluesky.law.columbia.edu/wp-content/uploads/sites/2/2022/11/brawley-e1667749440487.jpeg?w=150)
Insider Trading and Clinical Drug Trials
For at least a quarter century, the Securities and Exchange Commission (SEC) has pursued claims of unlawful insider trading where the information at issue was material to the stock price of the sponsor of a clinical trial. In recent years, …